Racura Oncology Ltd · ASX:RAC
Racura Oncology — Race Oncology — HealthInvest 2024
20 slides from Racura Oncology's conference presentation, Sep 18, 2024
Slide 1: Race to Present at HealthInvest 2024 Summit (ASX Announcement)
ASX Announcement Race to Present at HealthInvest 2024 Summit 18 September 2024 – Race Oncology Limited (“Race”) is pleased to share a copy of the presentation that will be presented to investors and industry colleagues at the inaugural HealthInvest 2024 investor evening in Sydney later today. Race E
Slide 2: Announcement contacts and authorisation
If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub https://announcements.raceoncology.com Race encourages all investors to go paperless by registering their details with the Company’s share regis
Slide 3: At the Heart of Cancer Care
S e p t e m b e r 2 0 2 4 For personal use only AT THE HEART OF CANCER CARE Pete Smith PhD, Executive Chair HealthInvest 2024 0 1 A S X : RA C | R A C E O NC O L O G Y L I M I T E D | A B N 6 1 1 4 9 3 1 8 7 4 9
Slide 4: Important Notice and Disclaimer
Important Notice and Disclaimer A T T H E Th e mat eri al i n t h is pres en ta ti o n h as b een prep ared by R ace On c ol o gy L i mi t ed ( AC N 14 9 31 8 749 ) ( Co mp any ) . H E A R T TH IS IS N O T A PR O SPEC TU S For personal use only Th i s pre sen t at io n i s n o t a p ros pe ct u s, p
Slide 5: Corporate snapshot
Corporate snapshot A T T H E Race Oncology is an ASX-listed, clinical stage biopharmaceutical company with a dedicated mission to be at the H E A R T heart of cancer care. For personal use only O F C A N C E R Key Data Race 12-month trading history C A R E ASX code RAC Share price $1.70 1 Market cap
Slide 6: Cancer survivorship
4 A T T H E H E A R T O F C A N C E R C A R E survivorship Cancer For personal use only
Slide 7: Cancer survivorship – life after treatment
Cancer survivorship – life after treatment A T T H E H E A R T New specialties such as cardio- By 2023, there will be 22.5m cancer For personal use only Ageing oncology are focused on reducing survivors in the US 1 with a 37% increased O F damage caused by treatments risk of cardiovascular disease f
Slide 8: Chemotherapy needs improvement
Chemotherapy needs improvement A T T H E H E A R T For personal use only O F C A N C E R Anthracyclines* are the most widely Current solution – exclude use in used class of chemotherapeutics. high-risk patients and limit C A R E They are highly effective, but can dosing of the drugs cause permanent
Slide 9: Anthracycline use is growing
Anthracycline use is growing1, 2, 3 A T T H E Estimated number of anthracycline doses used per year1 H E A R T For personal use only O F C A N C E R 24.49 22.98 • According to Data Bridge Market 21.55 Research, global anthracycline C A R E 20.22 usage is expected to increase by a 18.97 CAGR of 6.60%
Slide 10: Anthracyclines continue to be widely used
Anthracyclines continue to be widely used Lymphoma ABVD, CHOP/R-CHOP, For personal use only DA-EPOCH-R, others Small-cell lung cancer CAV Breast cancer AC/AC-T, FAC/CAF, FEC, others Oesophageal cancer ECF, EOX Acute myeloid leukemia 7+3/DA, ADE Bladder cancer Acute lymphoblastic leukemia Mono (Epi),
Slide 11: Clinical development of bisantrene
9 A T T H E H E A R T O F C A N C E R C A R E development of bisantrene Clinical For personal use only
Slide 12: Bisantrene's history of clinical success
Bisantrene’s history of clinical success A T T H E H E A R T Breast cancer 1 Acute Myeloid Leukaemia For personal use only O F 471 patients across 9 Phase 2 & 3 Approved in France in 1988, but Lederle (Pfizer) ended C A N C E R clinical trials commercial development of bisantrene due to solubility i
Slide 13: Building on bisantrene's history
Building on bisantrene’s history A T T H E H E A R T For personal use only Race has… O F • Created RC220, a new formulation of bisantrene which is more soluble C A N C E R and can be delivered intravenously 1 C A R E • RC220 preserves the PK/PD properties of the earlier clinically validated formulat
Slide 14: Bisantrene + doxorubicin = improved anti-cancer activity
Bisantrene + doxorubicin = A T improved anti-cancer activity 1 T H E H E A R T For personal use only Bisantrene shows potent cell-killing activity against a diverse range of human cancers when used alone and in combination with doxorubicin, the most commonly used anthracycline O F C A N C E R 10000
Slide 15: Bisantrene + doxorubicin = protecting the heart
Bisantrene + doxorubicin = protecting the heart 1 A T T H E H E A R T Bisantrene protects the hearts of mice from permanent damage Vehicle For personal use only caused by the anthracycline, doxorubicin Bisantrene O F Doxorubicin C A N C E R Heart protection was achieved using higher levels of Dox +
Slide 16: Clinical pipeline
Clinical pipeline A T T H E H E A R T For personal use only O F IND Asset Indication Sponsor Discovery Phase 1 Phase 2 Phase 3 Next milestone enabling C A N C E R Chaim Sheba RC110 Medical Successfully concluded in July C A R E Acute Myeloid Leukaemia Phase 2 Centre, 20241 Israel Cardioprotection +
Slide 17: Bisantrene market potential – world
Bisantrene market potential – world A T T H E H E A R T For personal use only Annual revenue generic Annual revenue bisantrene doxorubicin - 20231 cardioprotection + anti-cancer2 O F C A N C E R C A R E US$1.5b US$7b Note: Forecasted revenue reflect a 50% reduction to the physician-stated adoption r
Slide 18: Recent & upcoming milestones
Recent & upcoming milestones1 A T T H E H E A R T H2 CY2023 / H1 CY2024 H2 CY2024 H1 CY2025 For personal use only Interim results released from Sheba 2 O F Distinguished Oncologist Daniel Von Additional preclinical results on ✓ study of bisantrene RC110 in AML ✓ C A N C E R Hoff Joins as Consultant
Slide 19: Questions
For personal use only Questions Race Oncology A T T H E H E A R T O F C A N C E R C A R E 17
Slide 20: Contact
For personal use only Contact PETE SMITH Executive Chairman JA NE LOWE Investor & Media Relations +61 2 8051 3043 +61 411 117 774 peter.smith@raceoncology.com jane.lowe@irdepartment.com.au www.raceoncology.com Authorised for release by the Board A S X : R A C | R AC E O N C OL O G Y L IM I T E D | A